期刊文献+

茴拉西坦联合尼莫地平治疗阿尔茨海默病的临床观察 被引量:2

Clinical observation of Aniractam and Nimodiping in treatment of Alzheimer's diease
原文传递
导出
摘要 目的观察茴拉西坦联合尼莫地平治疗阿尔茨海默病的疗效。方法将114例阿尔茨海默病(AD病)患者随机分为治疗组和对照组,治疗组采用茴拉西坦胶囊0.2g/次3次/天,并加用尼莫地平片20mg/次3次/d;对照组单用尼莫地平片,用法同治疗组。疗程结束后,对两组患者依照阿尔茨海默病认知功能评价量表(ADAScog)标准评估,比较两组疗效。结果治疗组总有效率85.9%,对照组总有效率66.7%,两组有效率有统计学差异(P<0.05),总体安全性良好。结论茴拉西坦联合尼莫地平治疗阿尔茨海默病的治疗效果明显,副作用小,适合临床推广应用。 Objective To observe the clinical efficacy of Aniracetam and Nimodipine in treatment of Alzheimer's disease (AD). Methods The 114 patients of alzheimer's disease (AD) were randomly divided into treatment group and control group, Treatment group using Aniracetam capsule 0. 2 g/three times/day, and combined with Nimodipine 20 mg/three times per day; The control group use Nimodipine , and the usage is the same to Treatment group. After the treatment, according to the alzheimer's disease in patients with two groups of cognitive function assessment scale (ADAS - cog) standard assessment, to compare two groups of curative effect. Results The treatment group total effectiveness 85.9%, control group total effectiveness 66.7% , two groups of efficient statistically significant (P 〈 0.05 ) , the overall safety is good. Conclusion Aniracetam and Nimodipine in treatment of Alzheimer'sdisease(AD)is obvious, small side effects, suitable for clinical application.
作者 王会丛
出处 《医药论坛杂志》 2016年第1期32-33,共2页 Journal of Medical Forum
关键词 茴拉西坦 尼莫地平 阿尔茨海默病 Aniracetam Nimodipine Alzheimer's disease (AD)
  • 相关文献

参考文献5

二级参考文献58

  • 1于欣,王华丽,李淑然,陈玉芳,李海东,贺军.ADAS-Cog中文版区分轻、中度阿尔茨海默病的能力[J].中国心理卫生杂志,2005,19(1):31-33. 被引量:20
  • 2Taupin P.Adult neurogenesis,neural stem cells and Alzh-ermer's disease:developments,limitations,problems and promises[J].Curr Alzheimer Res,2009,6(6):461-470. 被引量:1
  • 3Snitz BE,O' Meara ES,Carlson MC,et al.Ginkgo biloba for preventing cognitive decline in older adults:a randomized trial[J].JAMA,2009,302(24):2663-2670. 被引量:1
  • 4Zec RF,Landreth ES,Vicari SK,et al.Alzheimer Disease Assessment Scale:A subtest analysis[J].Alzheimer Dis Assoc Disord,1992,6 a:164-181. 被引量:1
  • 5Wang HL,Yu X,Li S,et al,The Cognitive Subscale of Alzheimer's Disease Assessment Scale,Chinese Version in Staging of Alzheimer Disease[J].Alzheimer Dis Assoc Diisord,2004,18(4):231-235. 被引量:1
  • 6Benge JF,Balsis S,Geraci L,et al.How well do the ADAS-cog and its subscales measure cognitive dysfunction in Alzheimer's disease?[J].Dement Geriatr Cogn Disord,2009,28(1):63-69. 被引量:1
  • 7Pyo G,Elble RJ,Ala T,Markwell SJ.The characteristics of patients with uncertain/mild cognitive impairment on the Alzheimer disease assessment scale-cognitive subscale[J].Alzheimer Dis Assoc Dosord,2006,20(1):16-22. 被引量:1
  • 8American Psychiatric Association.Diagnostic and Statistical Manual of Mental Disorders[M].4th Ed.Washington,DC:American Psychiatric Association,1994. 被引量:1
  • 9Morris JC.The Clinical Dementia Rating(CDR):current version and scoring rules[J].Neurology,1993,43(11):2412-2414. 被引量:1
  • 10Petersen RC,Doody R.Kurz A,et a1.Current concepts in mild cognitive impairment[J].Arch Neurol,2001,58(2):1985-1992. 被引量:1

共引文献35

同被引文献11

引证文献2

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部